Source: European Journal of Clinical Pharmacology. Unidade: FM
Subjects: TABAGISMO, POLIMORFISMO, EXPRESSÃO GÊNICA, FARMACOGENÉTICA, PROMOÇÃO DA SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOMAZ, Paulo Roberto Xavier et al. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. European Journal of Clinical Pharmacology, v. 71, n. 9, p. 1067-1073, 2015Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs00228-015-1896-x. Acesso em: 20 set. 2024.APA
Tomaz, P. R. X., Santos, J. R., Issa, J. S., Abe, T. O., Gaya, P. V., Krieger, J. E., et al. (2015). CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. European Journal of Clinical Pharmacology, 71( 9), 1067-1073. doi:10.1007/s00228-015-1896-xNLM
Tomaz PRX, Santos JR, Issa JS, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy [Internet]. European Journal of Clinical Pharmacology. 2015 ; 71( 9): 1067-1073.[citado 2024 set. 20 ] Available from: http://link.springer.com/article/10.1007%2Fs00228-015-1896-xVancouver
Tomaz PRX, Santos JR, Issa JS, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy [Internet]. European Journal of Clinical Pharmacology. 2015 ; 71( 9): 1067-1073.[citado 2024 set. 20 ] Available from: http://link.springer.com/article/10.1007%2Fs00228-015-1896-x